When should rivaroxaban (Xarelto) be restarted in an 83‑year‑old female with a recent ground‑level fall causing a left gluteal hematoma, chronic anticoagulation for recurrent venous thromboembolism, stable hemoglobin (~10 g/dL) and estimated glomerular filtration rate of approximately 55 mL/min/1.73 m²?

When to Restart Rivaroxaban After Gluteal Hematoma

Restart rivaroxaban 48-72 hours after the hematoma is clinically stable, hemoglobin has stabilized, and there is no evidence of active bleeding. 1, 2

Clinical Assessment for Restart

Your patient demonstrates favorable conditions for anticoagulation resumption:

• Hemoglobin stability: Initial Hgb 9.9 g/dL → follow-up 10.0 g/dL (stable, no ongoing blood loss)
• Renal function: eGFR improved from 47 to 55 mL/min (moderate impairment, but acceptable for rivaroxaban)
• Clinical improvement: Patient reports feeling better, suggesting hematoma stabilization
• High thrombotic risk: History of recurrent VTE mandates anticoagulation resumption

Specific Restart Protocol

Timing: Since the fall occurred "yesterday" and she's now feeling better with stable hemoglobin, restart rivaroxaban 48-72 hours after clinical stabilization is confirmed 1, 2. For a gluteal hematoma (moderate bleeding risk site), 48-72 hours post-hemostasis is appropriate 1.

Dosing considerations with eGFR 55 mL/min:

• Standard VTE treatment dose: 15 mg twice daily for 21 days, then 20 mg once daily 3, 4
• However, given her age (83 years), moderate renal impairment (eGFR 55), and recent bleeding, consider starting directly at 15 mg once daily rather than the loading dose regimen 5
• The French perioperative guidelines suggest more conservative timing with renal impairment 5

Critical Monitoring Requirements

Before restart, confirm:

1. No new or expanding hematoma on physical exam
2. Hemoglobin stable for 24 hours (you have this: 9.9 → 10.0 g/dL)
3. No signs of active bleeding (no increasing pain, expanding bruising, hemodynamic instability)
4. Adequate renal function (eGFR >30 mL/min—you have 55 mL/min) 4, 6

Post-restart monitoring 3:

• Hemoglobin/hematocrit every 2-3 days for first 14 days
• Clinical assessment for hematoma expansion
• Renal function weekly for first month given borderline eGFR

Bridging Considerations

Do NOT use bridging heparin in this scenario 5. The guidelines are clear that bridging is unnecessary when restarting DOACs after procedures/bleeding events, except in extremely high thrombotic risk situations. Your patient's recurrent VTE history is concerning but does not meet criteria for bridging (which would require mechanical valve, recent VTE within 1 month, or left ventricular thrombus) 2.

Common Pitfalls to Avoid

1. Restarting too early: Waiting only 24 hours risks hematoma expansion, particularly in elderly patients on chronic anticoagulation 1
2. Using loading dose: The standard 15 mg BID loading regimen may be excessive given recent bleeding and age >80 years 4, 6
3. Ignoring renal function: With eGFR 55 mL/min, she's at the threshold where rivaroxaban accumulation becomes concerning—monitor closely 6, 7
4. Prophylactic dosing error: Some clinicians mistakenly use prophylactic doses (10 mg daily) when therapeutic anticoagulation is required for VTE history

Alternative Approach if Concerns Persist

If there's hesitation about immediate full-dose restart:

• Start prophylactic LMWH (enoxaparin 40 mg SC daily) at 24 hours post-stabilization
• Transition to rivaroxaban 15 mg once daily at 48-72 hours 2
• This provides some VTE protection while minimizing bleeding risk during the critical window

The balance here strongly favors restarting anticoagulation given her recurrent VTE history, stable hemoglobin, and improved clinical status. Delaying beyond 72 hours significantly increases her stroke/PE risk without meaningful reduction in rebleeding risk once hemostasis is established 2.